After several months of hard work, we have finalised the first phase of our trials! During this phase we have been able to validate our new LAMP assay with 183 samples and show 90.5% sensitivity and 100% specificity with detection in under 20 minutes. We have also incorporated the assay on our platform and demonstrated average detection of 12.9 min with 40 samples.
Our publication is available online: https://www.medrxiv.org/content/10.1101/2020.06.29.20142349v1 .
We are excited to announce that Phase 2 will start imminently as we will be heading to Charing Cross Hospital to validate our new test from sample to result. Stay tuned for more!
We have started validating the technology in the lab for testing of COVID-19 and have set up a plan for a trial in the next month at Charing Cross Hospital, one of the largest hospitals in London.
Rapid testing for #COVID19 is vital! We are doing our part and following a huge effort from a great team, Lacewing is now ready! We are now validating with clinical samples in the lab.
The plan is
- April – May : Finalise clinical validation in the lab.
- June : Validate the technology at Charing Cross Hospital.
We are aiming to produce 1000 tests per month to help healthcare staff and hospitalised patients get tested for COVID-19.
We had the amazing opportunity to showcase Lacewing at the POST UK superbugs event on antimicrobial resistance. The presentation raised interest around the need for diagnostics while allowing for great discussions.
Lacewing is part of the DIAMONDS project which has been awarded €22.5m EU funding over 5 years to develop a rapid test for severe infections using personalised gene signatures. The test will be trialled in hospitals across Europe.
The project is very multidisciplinary and the diagnostic arm involves Lacewing as well as BioMerieux. In this project, we aim to develop a rapid point of care test using microchip technology to detect the gene signatures.
Lacewing was featured at the Imperial Lates events ‘Infectious’ and ‘Science Without Borders’! We were thrilled to tell you about our project and our recent experience validating the device in Ghana!
Lacewing has reached Africa!
The team has headed to Ghana to trial Lacewing with malaria infections. We were warmly welcome by the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Accra and attended the WACCBIP research conference.
Meanwhile, we were working hard in the lab to validate the technology with stored clinical samples of malaria patients. The trip was productive as we have gathered a large set of data on Lacewing.